MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-26-0951

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2026

Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Nguyen Daniel, Kantarjian Hagop M, Bidikian Aram, Manuel Christopher M, Qiao Wei, Ning Jing, DiNardo Courtney D, Kadia Tapan M, Daver Naval, Borthakur Gautam, Jabbour Elias, Yilmaz Musa, Maiti Abhishek, Sasaki Koji, Montalban-Bravo Guillermo, Chien Kelly, Hammond Danielle, Pierce Sherry, Andreeff Michael, Ravandi Farhad, Short Nicholas J, Garcia-Manero Guillermo, Issa Ghayas C

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Outcomes in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) remain discouraging despite the rapid expansion of treatment paradigms over the past decade. Clinicians must often decide between conventional salvage treatment regimens or enrollment in clinical trials.

EXPERIMENTAL

DESIGN

We retrospectively identified 657 patients with AML in second treatment salvage and compared the outcomes of those who received investigational agents (n = 354) with conventional salvage regimens (n = 303).

RESULTS

Conventional salvage was associated with higher response rates [complete response (CR) or CR with incomplete count recovery rate: 22% vs. 12%, P = 0.0008] and higher early mortality rates (60-day mortality: 17% vs. 7%, P = 0.0002). There was no difference in rates of bridging to allogeneic stem cell transplant (7% vs. 10%, P = 0.2), event-free survival (EFS; median: 1.5 vs. 2 months, P = 0.9), or overall survival (OS; median: 4.1 vs. 4.5 months, P = 0.8). A subgroup analysis of conventional regimens showed improved EFS (median EFS: 3.6 vs. 1.4 months, P = 0.004) and a trend toward improved OS (median OS: 7.5 vs. 3.8 months, P = 0.06) with the addition of venetoclax in venetoclax-naïve patients.

CONCLUSIONS

Enrollment of R/R patients in clinical trials is a suitable alternative to conventional salvage regimens, offering novel therapeutic approaches to improve upon the historically dismal outcomes in this setting.

Для цитирования: Nguyen Daniel, Kantarjian Hagop M, Bidikian Aram, Manuel Christopher M, Qiao Wei, Ning Jing, DiNardo Courtney D, Kadia Tapan M, Daver Naval, Borthakur Gautam, Jabbour Elias, Yilmaz Musa, Maiti Abhishek, Sasaki Koji, Montalban-Bravo Guillermo, Chien Kelly, Hammond Danielle, Pierce Sherry, Andreeff Michael, Ravandi Farhad, Short Nicholas J, Garcia-Manero Guillermo, Issa Ghayas C. Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. DOI: 10.1158/1078-0432.ccr-26-0951.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.